Wall Street brokerages expect Mylan NV (NASDAQ:MYL) to announce $1.29 earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have made estimates for Mylan’s earnings, with estimates ranging from $1.27 to $1.32. Mylan posted earnings per share of $1.30 during the same quarter last year, which indicates a negative year-over-year growth rate of 0.8%. The company is expected to report its next quarterly earnings results on Tuesday, February 25th.
According to Zacks, analysts expect that Mylan will report full year earnings of $4.31 per share for the current financial year, with EPS estimates ranging from $4.20 to $4.40. For the next financial year, analysts expect that the business will report earnings of $4.47 per share, with EPS estimates ranging from $4.30 to $4.67. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Mylan.
Mylan (NASDAQ:MYL) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $1.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.03. Mylan had a net margin of 0.42% and a return on equity of 18.80%. The firm had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3.01 billion. During the same quarter last year, the company posted $1.25 EPS. The firm’s quarterly revenue was up 3.5% on a year-over-year basis.
Several equities research analysts have issued reports on the stock. Cfra downgraded shares of Mylan from a “hold” rating to a “sell” rating in a research note on Tuesday, November 5th. SunTrust Banks upped their price target on shares of Mylan from $25.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, September 12th. BidaskClub cut shares of Mylan from a “hold” rating to a “sell” rating in a report on Thursday, November 7th. Mizuho increased their target price on shares of Mylan from $25.00 to $27.00 and gave the stock a “neutral” rating in a report on Tuesday, July 30th. Finally, ValuEngine raised shares of Mylan from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. Three research analysts have rated the stock with a sell rating, six have given a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $27.97.
In other Mylan news, insider Goulds Bruce 8,000,000 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. Corporate insiders own 0.81% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Mylan by 19.2% during the second quarter. Vanguard Group Inc. now owns 56,048,375 shares of the company’s stock valued at $1,067,160,000 after buying an additional 9,026,215 shares during the last quarter. Banco Santander S.A. bought a new stake in shares of Mylan during the 3rd quarter valued at $55,384,000. Nuveen Asset Management LLC raised its stake in shares of Mylan by 824.3% during the 2nd quarter. Nuveen Asset Management LLC now owns 1,681,501 shares of the company’s stock valued at $31,898,000 after purchasing an additional 1,499,579 shares during the period. Point72 Asset Management L.P. grew its position in Mylan by 312.6% during the second quarter. Point72 Asset Management L.P. now owns 1,769,543 shares of the company’s stock worth $33,692,000 after buying an additional 1,340,643 shares in the last quarter. Finally, AQR Capital Management LLC grew its position in Mylan by 11.0% during the second quarter. AQR Capital Management LLC now owns 11,247,227 shares of the company’s stock worth $213,473,000 after buying an additional 1,111,009 shares in the last quarter. Institutional investors own 84.19% of the company’s stock.
Shares of MYL traded up $0.44 during midday trading on Thursday, reaching $17.70. The stock had a trading volume of 5,179,400 shares, compared to its average volume of 7,612,079. Mylan has a 1-year low of $16.63 and a 1-year high of $35.45. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.43 and a quick ratio of 0.84. The company’s fifty day simple moving average is $18.65 and its two-hundred day simple moving average is $19.46. The company has a market cap of $8.91 billion, a price-to-earnings ratio of 3.86, a PEG ratio of 0.93 and a beta of 1.75.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Further Reading: What is a good rate of return for a mutual fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.